CLLS
Cellectis SANASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$323.50M
P/E Ratio
—
EPS
$-0.67
Beta
2.75
52W High
$5.48
52W Low
$1.35
50-Day MA
$3.70
200-Day MA
$3.80
Dividend Yield
—
Profit Margin
-89.50%
Forward P/E
—
PEG Ratio
0.00
About Cellectis SA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Fundamentals
| Revenue (TTM) | $75.11M |
| Gross Profit (TTM) | $75.11M |
| EBITDA | $-32.75M |
| Operating Margin | -333.40% |
| Return on Equity | -76.30% |
| Return on Assets | -8.43% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $0.82 |
| Price-to-Book | 5.22 |
| Price-to-Sales (TTM) | 4.31 |
| EV/Revenue | 3.242 |
| EV/EBITDA | -3.90 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -37.30% |
| Shares Outstanding | $72.61M |
| Float | $46.69M |
| % Insiders | 0.00% |
| % Institutions | 16.54% |
Historical Volatility
HV 10-Day
65.78%
HV 20-Day
55.82%
HV 30-Day
54.99%
HV 60-Day
67.49%
HV Rank
11.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.60 target)
1
Strong Buy2
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026